Abstract: The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.

Abstract: An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP).

Abstract: Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.

Abstract: A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen.

Abstract: Secreted proteins as detection markers for insect vector and graft transmitted citrus disease are described. Method and kits for detecting the secreted proteins are provided.

Abstract: The invention generally relates to using magnetic particles and alternating magnet fields to separate a target analyte from a sample. In certain embodiments, methods of the invention involve contacting a sample with magnetic particles including first moieties specific for a target analyte, thereby forming target/particle complexes in the sample, flowing the sample through a channel including second moieties attached to at least one surface of the channel, applying alternating magnetic fields to the flowing sample to result in target/particle complexes being brought into proximity of the surface to bind the second moieties and unbound particles remaining free in the sample, binding the target/particle complexes to the second moieties, and washing away unbound particles and unbound analytes of the sample.

Abstract: Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis.

Abstract: The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.

Abstract: The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

Abstract: Provided is a modified antibody which enables the quantitative measurement of the amount of a heparin/PF4 complex, an onset factor of heparin-induced trombocytopenia (HIT), without the influence of the presence of PF4, and which can be used as an HIT antibody standard specific for the heparin/PF4 complex. The modified antibody is prepared by linking a human IgG, or an antibody fragment derived from a human IgG, to a monoclonal antibody obtained by immunizing an animal (excluding a human) with the heparin/PF4 complex.

Abstract: The invention relates to monoclonal antibodies which are reactive with an epitope in the polypeptide represented by amino acid sequence 236 to 251 or 264 to 279 of the human CGA amino acid sequence. The invention further relates to the use of these monoclonal antibodies in an immunoassay for CGA, to immunoreagents comprising any of these two antibodies, and to test kits for the determination of CGA containing immunoreagents based on both of the monoclonal antibodies.

Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Abstract: The invention relates to new peptides and to their use in the diagnosis of celiac disease.

Abstract: X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical, for estimating the binding selectivity of a chemical versus chemical analogs, for measuring post-translational modifications of proteins, and for drug manufacturing.

Abstract: The present disclosure features a variety of compositions, kits, and methods that are useful for, inter alia, detecting and/or analyzing an interaction between two molecules, a target molecule and a target-specific binding agent which can be, e.g., proteins, nucleic acids, saccharides or polysaccharides, small molecules, or combinations of any of the foregoing. The compositions, kits, and methods can also be used, e.g., to detect the presence or absence of an enzymatic activity (e.g., a kinase activity, a protease activity, or a phosphatase activity) in a sample; to identify a compound that modulates an interaction between two molecules; or to identify compounds that modulate the activity of an enzyme.

Abstract: The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.

Abstract: An assay method for determining transcobalamin saturation wherein a transcobalamin containing liquid sample is contacted with a porous substrate with immobilized thereon a transcobalamin immobilizing ligand and with a reporter-labelled transcobalamin binding partner and wherein signals from reporter labels which become immobilized on said substrate are detected, characterized in that one of said ligand or said binding partner comprises a first ligand or binding partner capable of specific binding to holo transcobalamin and a second ligand or binding partner capable of binding to apo transcobalamin or to holo and apo transcobalamin.

Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.

Abstract: Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.